Search

The essential purpose of the research study is to determine the evolution of information technology and commercial biotechnology in the pharma industries. This research study depends upon data collection methods related to information technology and commercial biotechnology. The research was conducted in china, and the data was collected from Chinese pharma industries through specific questions. We used smart PLS software to measure the data and run results that included significant analysis, indicator correlation, the R square, colinearity statistical analysis, and the smart PLS Algorithm model and presented the discriminant validity analysis between independent and dependent variables. Information technology is an independent variable, and commercial biotechnology is a dependent variable. Overall result found a positive and significant evolution of information technology and commercial biotechnology in pharma industries. Therefore, information technology shows a vital role in the pharma industry. [ABSTRACT FROM AUTHOR]

The production of lactic acid (LA) through the microbial conversion of agro-industrial residuals is an important process in the biotechnology industry. The growth kinetics of 30 strains of lactic acid bacteria (LAB) isolated from agro-industrial residues were determined and nine strains were selected for microbioreactor fermentation. Lactiplantibacillus pentosus_70-1 (1.662) and L. pentosus_19-2 (1.563) showed the highest OD600 values, whereas the highest growth rates were observed for L. pentosus_19-2 (0.267 h−1) and Weissella soli_31 (0.256 h−1). The production of LA and acetic acid (AA), glucose consumption, and metabolic profiles were determined, without finding significant differences in the production of LA; however, W. soli_29 produced the highest amount of LA (20.833 gL−1) and was able to metabolize most of the studied carbohydrates. Based on these results, W. soli_29 was chosen for a 20 h fermentation in a 7 L bioreactor using both standard medium and milk whey supplemented medium. W. soli_29 produced 16.27 gL−1 and 7.21 gL−1 of LA in each of these mediums, respectively. These results show the underlying potential of Weissella strains for biotechnological applications. Additional analysis which should contemplate different agro-industrial residues and other conditions in bioreactors must be carried out. [ABSTRACT FROM AUTHOR]

Copyright of Nachrichten aus der Chemie is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

This study demonstrated the enzymatic hydroxylation of glycitin to 3′-hydroxyglycitin, confirming the structure by mass and nucleic magnetic resonance spectral analyses. The bioactivity assays further revealed that the new compound possessed over 100-fold higher 1,1-diphenyl-2-picrylhydrazine free-radical scavenging activity than the original glycitin, although its half-time of stability was 22.3 min. Furthermore, the original glycitin lacked anti-α-glucosidase activity, whereas the low-toxic 3′-hydroxyglycitin displayed a 10-fold higher anti-α-glucosidase activity than acarbose, a standard clinical antidiabetic drug. The inhibition mode of 3′-hydroxyglycitin was noncompetitive, with a Ki value of 0.34 mM. These findings highlight the potential use of the new soy isoflavone 3′-hydroxyglycitin in biotechnology industries in the future. [ABSTRACT FROM AUTHOR]

Purpose: Biotechnology has gained such prominence in the past years that approximately 50% of new drugs developed worldwide are of biotechnological origin. Some of the Covid-19 vaccines are a good example of this development. However, biotechnology R&D projects are characterized by high costs, prolonged development times, and a high degree of uncertainty and failure. Only few types of financial agents undertake such risky investments, among which are venture capital firms. In this paper, we analyse the signals that influence suchlike venture capital investment decisions. The very high level of risk, which differentiates biotechnology firms from other technology companies, justifies an analysis focused solely on biotechnology firms. Design/methodology: Hypotheses about the effectiveness of these signals are validated by means of a probit regression with panel data on a sample of 210 biotechnology companies established in Spain over a ten-year period. Findings: A positive and negative signalling effect has been found for some of the phenomena analysed, which validate the proposed model. Research limitations/implications: A convenience sample has been used for methodological reasons. Some phenomena that could have some effect on the venture capital investment decisions have not been possible to observe. Practical implications: It can be crucial for biotechnology firms for their managers to know which characteristics make these firms attractive to venture capital firms. Additionally, it is important to be aware of signals that, instead of favouring investment decisions, deter them. Originality/value: This is the first study conducted for the Spanish industry to focus on the first venture capital investment - rather than the typical focus on the amount invested- as an event that mitigates the information asymmetry level, and which includes also a distinction between four types of strategic alliance, the use of a probit regression with panel data, and a quantitative analysis on the biotech industry. As the Spanish biotechnology and venture capital industries differ from those established in other European countries, this work offers new elements of analysis, description, and comparison of these industries. In addition, the construction of a database on a sample of 210 Spanish biotechnology firms is unprecedented and can be used for future research. [ABSTRACT FROM AUTHOR]

Process development in the biotech industry leads to investments around hundred of millions of dollars. It is important to mitigate costs without neglecting the quality of process development. Biopharmaceutical process development is important for companies to develop new processes and be first to market, improve a pre‐established process, or start manufacturing a product available by patent expiry (biosimilars). Laboratory automation enables methodical and standardized process development. Miniaturization and parallelization empower laboratories to screen several experimental conditions and define operating windows for purification processes, improving process robustness. Together, they allow for fast and accurate process development in a fraction of the time and cost of nonminiaturized/nonparallel process development approaches. The most widely used High‐Throughput Screening technique is a liquid‐handling station and microfluidics is taking its first steps in process development. Both are attractive scale‐down tools for the characterization of bioprocesses and allow thousands of experiments to be performed per day. High‐Throughput Process Development (HTPD) has helped to achieve major breakthroughs in process optimization, both for upstream and downstream processing. Continuous processing is the next step in process development which leads to cost reduction, higher productivity and better quality control; the integration of upstream and downstream processes is seen as a major challenge. In this review, we will focus on the state‐of‐the‐art of miniaturized techniques for process development in the biotechnology industry, and how automation and miniaturization drive process development. A comparison between liquid‐handling stations and microfluidics is made and an indication is given of which tools are still lacking for HTPD in the context of Integrated Continuous Biomanufacturing. © 2021 The Authors. Journal of Chemical Technology and Biotechnology published by John Wiley & Sons Ltd on behalf of Society of Chemical Industry (SCI). [ABSTRACT FROM AUTHOR]

Purpose: The purpose of this study is to theoretically and empirically advance a concept of competitive antecedents to absorptive capacity (AC) research and to explain their relationship to a firm's innovative performance. A firm's competitive antecedents involve a relative advantage in a firm's ability to access external knowledge – (i.e. relative advantage in external knowledge flows) – and a relative advantage in appropriating these external knowledge flows (i.e. relative advantage in appropriability regime). Design/methodology/approach: By drawing on network and market share explanations, hypotheses were developed in which a firm's AC is argued to mediate the influence of these competitive antecedents on a firm's innovations. In using linear and negative binomial estimation methods, a mediation analysis of the US biotechnology industry was conducted. Findings: A firm's competitive antecedents have a positive influence on a firm's AC and that these influences indirectly impact a biotechnology firm's product innovations. Originality/value: While a firm's innovation is widely attributed to its AC, this study's concept of competitive antecedents shows that a firm's competitive advantage lies upstream from its AC. [ABSTRACT FROM AUTHOR]

Monitoring of bioprocesses is a challenge in designing modern systems for control. In the biotechnology industry, the lack of reliable hardware sensors for key variables related to the metabolism of microorganisms is a topical problem. This predetermines the progress of a scientific field that relies on the development of software sensors for immeasurable variables. In this paper, a new approach for the monitoring of class-controllable bioprocesses that evolve through various physiological states (metabolic regimes) is proposed. At the core of the approach is the potential to present total biomass as a sum of the biomass concentrations obtained during each of the metabolic regimes. Algorithms for estimation of immeasurable variables and their kinetics are here derived and applied using real experimental data. As a case-study, a fed-batch process for phytase production by E. coli is considered. Effectiveness of the method is proven by using two sets of real experiments. One is used to tune the software sensors and the other to verify the approach. The stability analyses are provided, as well. The obtained results and successful verification confirm the adaptive properties of the approach. The considered software sensors will be further built into an interactive system for training specialists/students of biotechnology. [ABSTRACT FROM AUTHOR]

Circumcised donut benzenoid systems are a class of polycyclic aromatic hydrocarbons (PAHs) derived from planar benzenoid networks by strategically eliminating a few hexagons. The study of donut benzenoid systems has been gaining ground because of their neoteric and fascinating characteristics like superaromaticity, ascribed to their unique structure. The distinct nature and properties of donut benzenoids open the door for applications in several industries such as biotechnology, electronics, pharmaceuticals and so on. The investigation of the properties of circumcised donut benzenoids and their relationship to the underlying molecular structures using graph-theoretical techniques is advantageous in the design and synthesis of new donut benzenoid compounds. Studies on topological indices have conclusively proved that they have a strong correlation to various properties of chemical compounds. They also provide a mathematical representation of the molecular structure for QSPR/QSAR techniques. In this paper, the degree-based molecular structural descriptors are calculated for two circumcised donut benzenoid structures using M-polynomial and edge partition techniques, effectively doubling the number of known topological indices for these structures. Also, the numerical values of these indices are computed and compared pictorially. [ABSTRACT FROM AUTHOR]

Since the manufacture of the first biotech product for a fledgling biopharmaceutical industry in 1982, Escherichia coli, has played an important role in the industrial production of recombinant proteins. It is now 40 years since the introduction of Humulin® for the treatment of diabetes. E. coli remains an important production host, its use as a cell factory is well established and it has become the most popular expression platform particularly for non-glycosylated therapeutic proteins. A number of significant inherent obstacles in the use of prokaryotic expression systems to produce biologics has always restricted production. These include codon usage, the absence of post-translational modifications and proteolytic processing at the cell envelope. In this review, we reflect on the contribution that this model organism has made in the production of new biotech products for human medicine. This will include new advancements in the E. coli expression system to meet the biotechnology industry requirements, such as novel engineered strains to glycosylate heterologous proteins, add disulphide bonds and express complex proteins. The biopharmaceutical market is growing rapidly, with two production systems competing for market dominance: mammalian cells and microorganisms. In the past 10 years, with increased growth of antibody-based therapies, mammalian hosts particularly CHO cells have dominated. However, with new antibody like scaffolds and mimetics emerging as future proteins of interest, E. coli has again the opportunity to be the selected as the production system of choice. [ABSTRACT FROM AUTHOR]

Gas-liquid-solid three-phase fluidized bed has been widely used in chemical, biotechnology and environmental industries for its advantages of large inter-phase contact area, high heat/mass transfer efficiency and intense reaction process. In this work, the bidirectional sinusoidal liquid pulsed GLS fluidized bed was proposed to improve the interphase relative velocity and reaction efficiency. The effects of particle properties and pulsed liquid amplitude/frequency on the flow characteristics were studied by numerical simulations and experiments. In a complete circulation period, the average axial solids holdup is larger near the middle region of the fluidized bed and gradually decreases along the upper and lower inlets. With the increase of pulsation amplitude or period, the axial average gas holdup distribution uniformity and the liquid-solid relative velocity increase significantly. Compared with the conventional upward gas-liquid-solid fluidized bed, the bidirectional fluidized bed can further improve the liquid-solid relative velocity and reaction efficiency. The obtained studies have important implications for better design, scale-up and operation of gas-liquid-solid multiphase fluidization systems. [Display omitted] • The bidirectional sinusoidal liquid pulsed GLS fluidized bed is investigated. • The flow characteristics are studied by simulations and experimental measurements. • A good agreement is achieved between the numerical and experimental results. • The liquid-solid relative velocity is more affected by pulsation amplitude/period. • The special fluidized bed can further improve the liquid-solid relative velocity. [ABSTRACT FROM AUTHOR]

Biomedical workflow applications' necessities have increased with the progress of the biotechnology industry and it involves large volumes of data which require large-scale computation. Due to the upcoming data deluge of biomedical data, processing and scheduling of the same in computing resources have presented many challenges. A biomedical workflow application requires heterogeneous resources for execution. Thus, it utilizes the advantage of cloud computing, as a cloud provides scalable high-performance computing resources. Scheduling of these workflows in the cloud is a crucial problem for which the proposed solution contributes greatly towards execution improvement. The proposed algorithm provides optimal and effective utilization of computational resources by novel scheduling of algorithms. Least Execution Time Cloud Workflow Scheduling (LETCWS) and Revised Heterogeneous Earliest Finish Time (RHEFT) algorithms are proposed and implemented in two distinct levels to schedule the biomedical workflow applications in such a way that it reduces the execution time while reducing the cost. The proposed algorithms are evaluated using the Workflowsim tool with real-world biomedical workflow applications. Experimental results illustrate the performance of scheduling workflow applications over the other existing approaches. The result shows that the proposed algorithm achieves better performance in terms of execution time and cost. [ABSTRACT FROM AUTHOR]

It is estimated that food fraud, where meat from different species is deceitfully labelled or contaminated, has cost the global food industry around USD 6.2 to USD 40 billion annually. To overcome this problem, novel and robust quantitative methods are needed to accurately characterise and profile meat samples. In this study, we use a glycomic approach for the profiling of meat from different species. This involves an O-glycan analysis using LC-MS qTOF, and an N-glycan analysis using a high-resolution non-targeted ultra-performance liquid chromatography-fluorescence-mass spectrometry (UPLC-FLR-MS) on chicken, pork, and beef meat samples. Our integrated glycomic approach reveals the distinct glycan profile of chicken, pork, and beef samples; glycosylation attributes such as fucosylation, sialylation, galactosylation, high mannose, α-galactose, Neu5Gc, and Neu5Ac are significantly different between meat from different species. The multi-attribute data consisting of the abundance of each O-glycan and N-glycan structure allows a clear separation between meat from different species through principal component analysis. Altogether, we have successfully demonstrated the use of a glycomics-based workflow to extract multi-attribute data from O-glycan and N-glycan analysis for meat profiling. This established glycoanalytical methodology could be extended to other high-value biotechnology industries for product authentication. [ABSTRACT FROM AUTHOR]

Although recombinant proteins are widely used in biotechnology and pharmaceutical industries, improving their solubility and stability is often a challenging issue. We recently discovered a class of highly unstructured heat-resistant obscure (Hero) proteins, which function to protect other "client" proteins in trans from various stresses in vitro and in vivo. Here, we show that fusion of Hero proteins in cis can enhance the molecular property of recombinant proteins. Fusion with Hero11 improved the otherwise challenging production of TAR DNA-binding protein of 43 kDa (TDP-43) in Escherichia coli. Moreover, fusing with Hero9 strongly protected the activity of firefly luciferase bearing destabilizing mutations against heat and other stress conditions. These data suggest that Hero proteins have the potential to be used as versatile stabilization tags for recombinant protein production. [ABSTRACT FROM AUTHOR]

Copyright of Lilloa is the property of Fundacion Miguel Lillo and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)